Clinical Trials

A completed Phase 2 clinical trial sponsored by Cytokinetics evaluated the therapeutic potential of Tirasemtiv for neurodegenerative disease management, specifically in patients with amyotrophic lateral sclerosis. This double-blind, randomized, placebo-controlled dose-titration study rigorously assessed the safety, tolerability, and pharmacodynamic response of fast skeletal muscle troponin activation.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01486849 Completed
Amyotrophic Lateral Sclerosis
Cytokinetics
2011-11 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Tirasemtiv (CK-2017357) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Tirasemtiv directly binds to the fast skeletal muscle troponin complex, sensitizing the sarcomere to calcium ions and augmenting muscle force production at submaximal calcium concentrations. This enhancement of skeletal muscle contractility offsets neuromuscular signaling deficits, offering therapeutic relevance for improving muscle strength and functional capacity in patients with amyotrophic lateral sclerosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.